New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:05 EDTAGIOAgios Pharmaceuticals announces AG-221 orphan drug designation
Agios Pharmaceuticals announced that the U.S. Food and Drug Administration has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia. AG-221 is an oral IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
08:08 EDTAGIOAgios Pharmaceuticals to present data at 20th Congress of EHA
Subscribe for More Information
May 19, 2015
08:57 EDTAGIOLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 18, 2015
07:37 EDTAGIOAgios Pharmaceuticals AG-120 granted FDA Fast Track designation
Subscribe for More Information
May 12, 2015
07:52 EDTAGIOLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use